These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51. [Molecular mechanisms in myeloproliferative diseases and myelodysplastic syndromes]. Harada H; Harada Y; Kimura A Nihon Rinsho; 2009 Oct; 67(10):1901-5. PubMed ID: 19860187 [TBL] [Abstract][Full Text] [Related]
52. The role of Runx1/AML1 and Evi-1 in the regulation of hematopoietic stem cells. Kumano K; Kurokawa M J Cell Physiol; 2010 Feb; 222(2):282-5. PubMed ID: 19847803 [TBL] [Abstract][Full Text] [Related]
54. Identification of RUNX1/AML1 as a classical tumor suppressor gene. Silva FP; Morolli B; Storlazzi CT; Anelli L; Wessels H; Bezrookove V; Kluin-Nelemans HC; Giphart-Gassler M Oncogene; 2003 Jan; 22(4):538-47. PubMed ID: 12555067 [TBL] [Abstract][Full Text] [Related]
55. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Yamashita N; Osato M; Huang L; Yanagida M; Kogan SC; Iwasaki M; Nakamura T; Shigesada K; Asou N; Ito Y Br J Haematol; 2005 Nov; 131(4):495-507. PubMed ID: 16281942 [TBL] [Abstract][Full Text] [Related]
56. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences. Kasashima K; Sakota E; Kozu T Biochimie; 2004; 86(9-10):713-21. PubMed ID: 15556282 [TBL] [Abstract][Full Text] [Related]
57. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes]. Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564 [TBL] [Abstract][Full Text] [Related]
58. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260 [TBL] [Abstract][Full Text] [Related]
59. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1. Li X; Vradii D; Gutierrez S; Lian JB; van Wijnen AJ; Stein JL; Stein GS; Javed A J Cell Biochem; 2005 Nov; 96(4):795-809. PubMed ID: 16149049 [TBL] [Abstract][Full Text] [Related]
60. Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult. Motoda L; Osato M; Yamashita N; Jacob B; Chen LQ; Yanagida M; Ida H; Wee HJ; Sun AX; Taniuchi I; Littman D; Ito Y Stem Cells; 2007 Dec; 25(12):2976-86. PubMed ID: 17823240 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]